ASX Research
[BUY] Bellevue Gold (ASX: BGL) – Contractor Hiccup Masks a Looming Cash Flow Inflection
Buy, A$1.90 target and 32.9 per cent upside per institutional sell-side research, as Bellevue Gold’s hedge book clears in FY27.
[BUY] Chrysos (ASX: C79) – Pipeline Depth Answers the FY27 Deployment Question
Buy rated by institutional sell-side research, A$10.26 target, about 50.9 per cent upside. Chrysos has a 24-unit high-confidence pipeline for FY27.
[BUY] Worley (ASX: WOR) – Growth Without the Lump Sum Risk
Buy-rated Worley kept 77 per cent of FY26 revenue reimbursable while pushing into full project delivery. Target A$13.00, 31.8% upside, 5.1% yield.
[BUY] Qantas (ASX: QAN) – The Fleet Renewal Is the Margin Story
Buy-rated Qantas targets a 10-12% international margin from FY32 against 3.7% in FY26. Target A$12.45, 32.6% upside, 4.2% fully franked yield.
[BUY] Amcor (ASX: AMC) – A 5.6% Yield as Volumes Turn
Amcor is a Buy with a A$81.40 target, 24.4% upside from A$65.44. June quarter volumes turned positive, EBIT rose 22%, and the unfranked yield is about 5.6%.
[BUY] Life360 (ASX: 360) – The Market Sold a 38% Revenue Quarter
Life360 grew revenue 38% and adjusted EBITDA 53% in the June quarter, yet the CDIs fell 19% on the day. We rate it a Buy with a A$30.95 target.
[BUY] Breville Group (ASX: BRG) – The Coffee Fear Is Priced In, The Margin Recovery Is Not
Breville Group (ASX: BRG) at A$31.05, on about 29x FY27 earnings and near its own ten-year average while peers re-rate. Buy, about 22% upside.
[BUY] BlueScope Steel (ASX: BSL) – Capex Peaks and Cash Flow Inflects
BlueScope Steel (ASX: BSL) at A$32.00, on 6x forward EBITDA against steel peers near 7x. Capex has peaked and free cash flow inflects. Buy, about 18% upside.
[BUY] Aristocrat Leisure (ASX: ALL) – A Billion-Dollar Interactive Path
Aristocrat Leisure (ASX: ALL) at A$61.40, charting a path to US$1bn in Interactive revenue by FY29 as iGaming and iLotteries scale. Buy, around 14% upside.
[BUY] ResMed (ASX: RMD) – Growth Levers in Place for a Re-Rate
Buy ResMed at A$26.68 with a A$46.70 target and 75% upside. The GLP-1 fear is fading, new growth levers are scaling, and it trades below medtech peers.